Welcome to CDC stacks |
Stacks Logo
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
 
 
Help
Clear All Simple Search
Advanced Search
HPV Vaccination and Complex Regional Pain Syndrome: Lack of Evidence
Filetype[PDF-147.88 KB]


Details:
No Related Documents.
You May Also Like:
  1. Adverse events following 9-valent human papillomavirus vaccine (9vHPV) reported to the Vaccine Adverse Event Reporting System (VAERS)
    Personal Author:
    Arana, Jorge
    Corporate Authors:
    National Center for Emerging and Zoonotic Infectious Diseases (U.S.). Immunization Safety Office.
    Conference Authors:
    United States. Advisory Committee on Immunization Practices. Meeting (2018 February 21-22 : Atlanta, GA)
    Published Date:
    4/19/18
    Series:
    ACIP meeting Human Papillomavirus (HPV) Vaccines Update
    Description:
    Presentations February 2018 Day 1Publication date from document properties.HPV-02-Arana-508.pdf
    File Type:
    Filetype[PDF - 522.88 KB]
  2. Quadrivalent HPV vaccine safety review and safety monitoring plans for nine-valent HPV vaccine in the United States
    Personal Author:
    Gee, Julianne; Weinbaum, Cindy; Sukumaran, Lakshmi; Markowitz, Lauri E.;
    Published Date:
    Mar 30 2016
    Source:
    Hum Vaccin Immunother. 2016; 12(6):1406-1417.
    Description:
    Quadrivalent human papillomavirus (4vHPV) vaccine was licensed for use in the United States in 2006 and through 2015 was the predominate HPV vaccine used. With the exception of syncope, a known preventable adverse event after any injected vaccination...
    File Type:
    Filetype[PDF - 446.81 KB]
  3. Vaccine safety monitoring systems and methods
    Personal Author:
    DeStefano, Frank
    Corporate Authors:
    National Center for Emerging and Zoonotic Infectious Diseases (U.S.). Immunization Safety Office
    Conference Authors:
    United States. Advisory Committee on Immunization Practices. Meeting (2019 October 23-24, 2019 : Atlanta, GA)
    Published Date:
    October 23. 2019
    Series:
    ACIP meeting Vaccine Safety
    File Type:
    Filetype[PDF - 1.53 MB]
  4. Coming Soon
    Safety of the 9-Valent Human Papillomavirus Vaccine
    Personal Author:
    Shimabukuro, Tom T.; Su, John R.; Marquez, Paige L.; Mba-Jonas, Adamma; Arana, Jorge E.; Cano, Maria V.;
    Published Date:
    November 18 2019
    Source:
    Pediatrics. 144(6)
    Description:
    BACKGROUND:The 9-valent human papillomavirus vaccine (9vHPV) was approved for females and males aged 9 to 26 years in 2014. We analyzed postlicensure surveillance reports to the Vaccine Adverse Event Reporting System (VAERS).METHODS:We searched VAERS...
    Public Access
    Available on:
    December 01, 2020
  5. Human papillomavirus (HPV)vaccine safety update
    Personal Author:
    Sukumaran, Lakshmi
    Corporate Authors:
    National Center for Emerging and Zoonotic Infectious Diseases (U.S.). Division of Healthcare Quality Promotion. Immunization Safety Office.
    Conference Authors:
    United States. Advisory Committee on Immunization Practices. Meeting (2015 October 21 : Atlanta, GA)
    Published Date:
    October 21, 2015
    Series:
    ACIP meeting Human Papillomavirus (HPV) Vaccines Update
    File Type:
    Filetype[PDF - 209.85 KB]